Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 14/20 | 0.68 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.67 |
| ▸ | PLA2G4A | P47712 | 1/20 | 0.51 |
| ▸ | HTT | P42858 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15559554 | 0.95 | EPHX2 (0.74) | ACHEEPHX2PLA2G4A | |
| SCHEMBL3655324 | 0.95 | EPHX2 (0.74) | ACHEEPHX2 | |
| SCHEMBL3629434 | 0.93 | EPHX2 (0.76) | ACHEEPHX2 | |
| SCHEMBL19400357 | 0.93 | EPHX2 (0.76) | ACHEEPHX2 | |
| SCHEMBL1077924 | 0.93 | EPHX2 (0.76) | ACHEEPHX2 | |
| SCHEMBL19400363 | 0.93 | EPHX2 (0.76) | ACHEEPHX2 | |
| SCHEMBL3625938 | 0.93 | EPHX2 (0.76) | ACHEEPHX2 | |
| SCHEMBL19400387 | 0.93 | EPHX2 (0.76) | ACHEEPHX2 | |
| SCHEMBL19400416 | 0.93 | EPHX2 (0.76) | ACHEEPHX2 | |
| SCHEMBL15551259 | 0.91 | ACHE (0.63) | ACHEEPHX2PLA2G4AHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2014018913-A2 | SANTACRUZAMATE A COMPOSITIONS AND ANALOGS AND METHODS OF USE | UNIVERSITY OF CONNECTICUT (US) | 2014-01-30 | — | — | WO | disclosed |
| EP-2673269-A1 | HETEROCYCLIC COMPOUNDS AS PI3 KINASE INHIBITORS | F.HOFFMANN-LA ROCHE AG (CH) | 2013-12-18 | — | — | EP | disclosed |
| WO-2012107465-A1 | HETEROCYCLIC COMPOUNDS AS PI3 KINASE INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2012-08-16 | — | — | WO | disclosed |
| EP-1654231-B1 | CONJUGATE COMPOUNDS AND METHODS FOR REDUCING THE RISK OF EPILEPTIC OCCURRENCE OR FOR TREATMENT OF SEIZURE DISORDERS | DPHARM LTD (IL) | 2012-02-01 | — | — | EP | disclosed |
| EP-2326653-A1 | NEW (POLY)AMINOALKYLAMINOALKYLAMIDE, ALKYL-UREA, OR ALKYL-SULFONAMIDE DERIVATIVES OF EPIPODOPHYLLOTOXIN, A PROCESS FOR PREPARING THEM, AND APPLICATION THEREOF IN THERAPY AS ANTICANCER AGENTS | Pierre Fabre Médicament (FR) | 2011-06-01 | — | — | EP | disclosed |
| US-20100311694-A1 | Set of Geldanamycin Derivatives and Their Preparation Methods | INSTITUTE OF MEDICINAL BIOTECHNOLOGY, CHINESE ACADEMY OF MEDICAL SCIENCES (CN) | 2010-12-09 | — | — | US | disclosed |
| EP-2253621-A1 | A SET OF GELDANAMYCIN DERIVATIVES AND THEIR PREPARATION METHODS | Institute Of Medicinal Biotechnology, Chinese Academy of Medical Sciences (CN) | 2010-11-24 | — | — | EP | disclosed |
| CN-101835778-A | Hdac inhibitor | ARQULE INC | 2010-09-15 | — | — | CN | disclosed |
| WO-2010020663-A1 | NEW (POLY)AMINOALKYLAMINOALKYLAMIDE, ALKYL-UREA, OR ALKYL-SULFONAMIDE DERIVATIVES OF EPIPODOPHYLLOTOXIN, A PROCESS FOR PREPARING THEM, AND APPLICATION THEREOF IN THERAPY AS ANTICANCER AGENTS | PIERRE FABRE MEDICAMENT (FR) | 2010-02-25 | — | — | WO | disclosed |
| EP-1598067-B1 | Carbamic acid compounds comprising an amide linkage for the treatment of malaria | TOPOTARGET UK LTD (GB) | 2009-05-06 | — | — | EP | disclosed |
| EP-1335898-A1 | CARBAMIC ACID COMPOUNDS COMPRISING AN AMIDE LINKAGE AS HDAC INHIBITORS | Prolifix Limited (GB) | 2003-08-20 | — | — | EP | disclosed |
| WO-2002026696-A1 | CARBAMIC ACID COMPOUNDS COMPRISING AN AMIDE LINKAGE AS HDAC INHIBITORS | PROLIFIX LIMITED (GB) | 2002-04-04 | — | — | WO | disclosed |
| EP-1102762-A2 | 2-SUBSTITUTED-1-PIPERIDYL BENZIMIDAZOLE COMPOUNDS AS ORL1-RECEPTOR AGONISTS | PFIZER INC. (US) | 2001-05-30 | — | — | EP | disclosed |
| WO-2000008013-A2 | 2-SUBSTITUTED-1-PIPERIDYL BENZIMIDAZOLE COMPOUNDS AS ORL1-RECEPTOR AGONISTS | PFIZER PHARMACEUTICALS INC. (JP) | 2000-02-17 | — | — | WO | disclosed |
| EP-0226304-B1 | COMPOSITION CONTAINING A PENEM OR CARBAPENEM ANTIBIOTIC | SANKYO COMPANY LIMITED (JP) | 1991-08-28 | — | — | EP | disclosed |
| EP-0290211-A1 | Dihydropyridines | Pfizer Limited (GB) | 1988-11-09 | — | — | EP | disclosed |
| US-4757066-A | Reduces renal toxicity | SANKYO COMPANY LIMITED (JP) | 1988-07-12 | — | — | US | disclosed |
| EP-0226304-A1 | Composition containing a penem or carbapenem antibiotic | SANKYO COMPANY LIMITED (JP) | 1987-06-24 | — | — | EP | disclosed |
| EP-0080695-B1 | PHYSIOLOGICALLY ACTIVE SUBSTANCE FA-5859, ITS DERIVATIVE; THEIR PRODUCTION AND ANTIDIABETIC AGENTS CONTAINING SAID COMPOUNDS | Takeda Chemical Industries, Ltd. (JP) | 1985-04-17 | — | — | EP | disclosed |
| US-4216309-A | BACTERICIDES | ABBOTT LABORATORIES (US) | 1980-08-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100311694-A1 | Set of Geldanamycin Derivatives and Their Preparation Methods | HSP90AA1, HSP90AB1, HSP90B1 | ACHE 4761/4885EPHX2 3355/4885PLA2G4A 3675/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.